Ropes & Gray Represents Sarepta Therapeutics in Global Settlement and Licensing Deal with BioMarin Pharmaceutical
A Ropes & Gray team represented Sarepta Therapeutics in a global settlement and license agreements with BioMarin Pharmaceutical for the marketed Duchenne muscular dystrophy (DMD) therapy EXONDYS 51and all future exon-skipping drug treatments under a $35 million plus settlement of the companies’ patent dispute over the technology. The agreements were announced on July 18. Under terms of the agreement, Sarepta will pay BioMarin milestone and royalty payments with respect to drugs using the DMD technology.
The Ropes & Gray team was led by intellectual property transactions partner David McIntosh and included life sciences associate Rajarshi Banerjee (all of Boston).